TickerKhojCompany figuresAvailable
Data date: 2026-11-05
Pharmaceuticals · Pharmaceuticals: Major · NSE: EVONILE · Company data updated 2026-11-05
Evonile Pharma Limited
₹1,716.5+0.13% on 5 NovHealth: Weak 2/10
In plain words
Price: 4.6% below its 52-week high of ₹1,799.6.
A description of the data, not a recommendation.
Data dates & coverage4 / 5 sources available
Price historyAvailable
Latest session: 2026-11-05 · 2 records
Quarterly resultsAvailable
Latest reported quarter: Date not supplied · 0 records
ShareholdingUnavailable
Latest reported quarter: Date not supplied
Company eventsAvailable
Latest listed event: Date not supplied · 0 records
Dates belong to each source, not to a live price feed. An available source can still be delayed. A saved copy is shown when a newer response could not be used; unavailable data does not mean zero activity. See market data status →
Key figures
Price
₹1,716.5
Market cap
₹4,288 cr
P/E
—
P/B
5.5
ROE
11.6%
ROCE
11.8%
Debt / equity
0
Dividend yield
1.44%
1-year return
0.4%
52-week high
₹1,799.6
52-week low
₹1,600.1
Operating margin
12.1%
Growth
| Revenue (last 12 months) | ₹336 cr |
| Net profit (last 12 months) | ₹-4 cr |
| Sales growth, 3 years (yearly) | -2.2% |
| Profit growth, 3 years (yearly) | -3.4% |
At a glance
Efficiency
Moderate
ROE 11.6%, ROCE 11.8%, operating margin 12.1%: how much profit it earns on the money it uses.
Financials
Weak
Debt/equity 0.00, Profit growth -3.4% and sales growth -2.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
Strengths
- Virtually debt-free (debt/equity 0.1 or less).
Limitations
- Profit fell 3.4% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Evonile Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is the 52-week high and low of Evonile Pharma Limited?
The 52-week high is ₹1,799.6 and the 52-week low is ₹1,600.1.
Compared with similar companies
6 companies ranked
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Evonile Pharma Limited (this stock) | ₹1,716.5 | ₹4,288 cr | — | 5.5 | 11.6% | 11.8% | 0 | +0.4% |
| SMS Pharmaceuticals Limited vs EVONILE → | ₹516.7 | ₹4,930 cr | 45.9 | — | 14.3% | 13.9% | 0.46 | +83.9% |
| RPG Life Sciences Limited vs EVONILE → | ₹2,595.7 | ₹4,304 cr | 35.9 | — | 20.3% | 21.3% | 0.03 | +6.3% |
| Gufic Biosciences Limited vs EVONILE → | ₹434.45 | ₹4,278 cr | 59.3 | — | 10.1% | 15.3% | 0.61 | +32.1% |
| Aarti Drugs Limited vs EVONILE → | ₹445.15 | ₹4,148 cr | 17.8 | 2.4 | 13.4% | 13.2% | 0.37 | -11.6% |
| Kwality Pharmaceuticals Ltd vs EVONILE → | ₹3,687.3 | ₹3,885 cr | 47.2 | — | 22.6% | 31.4% | 0.39 | +111.1% |